iPLEDGE changes take effect for isotretinoin; bosakitug misses phase 2 atopic dermatitis goals, Aclaris says

A handheld dermatoscope standing upright on its ribbed grip, its round lens head facing the viewer.

Changes to the iPLEDGE program for isotretinoin took effect Nov. 15, allowing home monthly pregnancy tests and dropping monthly counseling documentation for patients who cannot become pregnant, according to the Food and Drug Administration (FDA).

Aclaris Therapeutics said bosakitug missed its primary and secondary end points in the phase 2 ADMIRATION trial in moderate to severe atopic dermatitis.

The weekly innovation roundup for dermatology, published every Sunday for the week before; every item links to its sources. Latest dermatology news · All specialties

Latest news

Tagged dermatology, from the daily briefing

  1. A dermatologist's sign-off on an AI skin cancer app raised patient trust 11 points and intent to follow its advice in a randomized study
  2. Upadacitinib safety at 52 weeks was similar after a switch from dupilumab in atopic dermatitis
  3. Stapokibart doubled itch response in moderate to severe prurigo nodularis, 64.0% vs 33.0% on placebo, in a phase 3 trial

See all the latest news